News | November 17, 2025
Briefs: Zydus, Divi's Laboratories and Relonchem
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
This is the first drug to receive a recommendation for this preventative indication in the European Union
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
The investment in land is Rs. 19.85 crore
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Subscribe To Our Newsletter & Stay Updated
